ST LOUIS, Feb. 2 /PRNewswire/ -- Veran Medical Technologies announced today that it has recently received two clearances (K093146 & K093995) from the U.S. Food and Drug Administration (FDA) to expand its indications for use of the ig4 Navigation platform.
The addition of the Ultrasound and 3D Fluoroscopic X-ray image modalities represent an important advancement for the ig4 Navigation platform. The ability to perform navigated cancer thermal ablation in lower cost imaging suites greatly increases the access and cost effectiveness of these procedures while maintaining the high-resolution image quality provided by conventional CT guidance.
"History has shown that the delivery of therapies in a cost effective, reliable, and efficient manner is as important as the therapy itself. We are excited about the near future when we will have tightly integrated therapy and delivery as well. These clearances allow Veran to be a market-unlocking key in driving the growth of minimally invasive interventional oncology procedures," said Les Carlson, Veran Director of Percutaneous Products.
About Veran Medical Technologies, Inc.
Veran Medical Technologies is a privately held medical device company focused on developing the next standard of care for minimally invasive delivery of interventional oncology therapies. Veran provides proprietary 4D registration capability for precise targeting of lesions via its electromagnetic navigation platform. The Veran platform aims to reduce procedure times, reduce radiation exposure for the clinical staff, and increase targeting accuracy enabling physicians to cost effectively treat patients with reduced co-morbidity risk. The company believes that by enabling minimally invasive, early stage treatments, it can increase patient survival and lower healthcare costs significantly. Veran Medical Technologies is headquartered in St. Louis, MO. To learn more about Veran Medical Technologies, please visit our website at http://www.veranmedical.com.